On this page:
Congressional Briefing Showcases CF Foundation Drug Development and Care Center Models
On February 11, 2014, the Cystic Fibrosis Foundation hosted a Congressional briefing to discuss the Foundation’s model of specialized, coordinated care and its innovative strategies for drug development, and how they can serve as an example for other rare, chronic diseases.
Senator Edward Markey (D-Mass.) speaks about the benefits of the CF model at a CF Foundation-hosted Congressional briefing.
The event, entitled “Personalized Medicine and Quality, Coordinated Care: The Cystic Fibrosis Model,” included a panel discussion of health care experts who specialize in CF, moderated by Robert J. Beall, Ph.D., President and CEO of the Cystic Fibrosis Foundation.
The briefing was co-sponsored by Senators Edward Markey (D-Mass.) and Kelly A. Ayotte (R-NH) and Congressional Cystic Fibrosis Caucus co-chairs Representatives Tom Marino (R-PA) and James McGovern (D-Mass). Panelists included Terence R. Flotte, M.D., dean of the University of Massachusetts Medical School; Carlos Perez, M.D., director of the Cystic Fibrosis Care Center at Geisinger Medical Center in Danville, Penn.; Paul Negulescu, Ph.D., vice president for research at Vertex Pharmaceuticals; and Megan Stacy, who has cystic fibrosis.
back to top
To ensure the voices of the CF community are heard in Washington, the Cystic Fibrosis Foundation submits testimony, comments and letters to Congress and federal agencies on health care policies vital to those with cystic fibrosis. Below, you will find statements that advocate for the CF community’s interests in three areas — federal investment in cystic fibrosis research and drug review, the development and review of CF treatments and health care reform.
Federal Investment in CF Research and Drug Review:
21st Century Cures Initiative
In 2014, Energy and Commerce Committee Chair Fred Upton (R-Mich.) and Representative Diana DeGette (D-Colo.) are spearheading the 21st Century Cures Initiative, an effort aimed at developing policies to accelerate the discovery, development and delivery of treatments and speed biomedical innovation. Through this initiative, the Energy and Commerce Committee is soliciting input from industry, patients, researchers, government agencies and other stakeholders about ways the government can incentivize and accelerate the development of cures. The CF Foundation has provided expertise in a number of areas to help inform this effort.
back to top
Health Care Reform and Regulatory Guidance
View the Cystic Fibrosis Foundation’s testimony, comments and letters highlighting the need for access to sophisticated, specialized care and health coverage for people with cystic fibrosis.
back to top
- Specialty Practitioner Payment Model Opportunities – Highlights the CF care center network as a model of efficient, effective care delivery and discusses the challenges and opportunities associated with improving payment and delivery for CF care through episode-based bundles.
- Medicare Part D Access to Immunosuppressants – Opposes a proposal by the Centers for Medicare and Medicaid Services that would hinder access to immunosuppressant medication for post-transplant patients.
- Federally-Facilitated Marketplaces – Urges the Centers for Medicare and Medicaid Services to ensure affordable access to CF care centers and treatments in federal health insurance marketplaces.
- Protection of Clinical Trial Data – Provides input to the FDA on ways to ensure the anonymity of patients in the clinical trial data submitted to the agency as part of medical product applications.
- Medicaid, CHIP and Exchanges – Cautions that the proposed rule may potentially increase obstacles to care for people with CF and other chronic illnesses by imposing barriers to life-saving treatments and increasing cost-sharing for patients and families.
- New pathway for expediting drug development – Suggests revisions to the FDA’s proposed new strategies for expediting the development of drugs for life-threatening illnesses, such as encouraging the agency to develop clear and specific guidelines, avoiding policies that could make treatments more expensive and consulting with external rare disease experts during drug review and approval.
- Evaluating the risks and benefits of new drugs – Evaluates the FDA’s proposed 5 year plan for implementing a new framework for benefit-risk evaluation in the human drug and biologic review process.
- New incentives for antibiotics development – Provides insight to the FDA on implementing the Generating Antibiotics Incentives Now (GAIN) Act, which encourages the development of new antibacterial and antifungal drugs to treat certain serious infections and creates a list of the pathogens that would be targeted by new products.
- New breakthrough therapies – Suggests a change to a new FDA program that would accelerate the review of treatments for serious diseases like cystic fibrosis. The comments also commend the agency for making its draft guidance on the new program clear, concise and responsive to the needs of those with CF.
Social Security Disability Programs
In February 2013, the Social Security Administration (SSA) proposed changes to the criteria it uses to determine if a patient with cystic fibrosis is eligible for disability benefits. The CF Foundation is concerned that some of these changes could hinder access to disability benefits for CF patients. View below letters to the SSA from the Cystic Fibrosis Foundation, cystic fibrosis care center directors and members of Congress expressing concern about the proposed changes.
Learn more about our briefings and testimonies prior to 2013.
back to top